Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study

Cancer ◽  
1993 ◽  
Vol 71 (7) ◽  
pp. 2342-2350 ◽  
Author(s):  
Joachim Yahalom ◽  
George Varsos ◽  
Zvi Fuks ◽  
Jane Myers ◽  
Bayard D. Clarkson ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hodgkin Lymphoma ◽  
Randomized Study ◽  
Stage I ◽  
Prospective Randomized Study ◽  
Low Grade ◽  
Intermediate Grade ◽  
Non Hodgkin Lymphoma

Radiation Therapy for Stage I Primary Orbital Non-Hodgkin's Lymphomas

1997 ◽  
Vol 83 (5) ◽  
pp. 822-825 ◽  
Author(s):  
Haldun Şükrü Erkal ◽  
Meltem Serin ◽  
Serpil Dizbay Sak ◽  
Ahmet Çakmak
Keyword(s):  
Radiation Therapy ◽  
Combination Chemotherapy ◽  
Disease Free Survival ◽  
Stage I ◽  
Entire Group ◽  
Low Grade ◽  
Intermediate Grade ◽  
Chop Regimen ◽  
Survival Probabilities ◽  
Hodgkin's Lymphomas

Aims and Background The orbit is an uncommon primary site for non-Hodgkin's lymphomas (NHL), and it accounts for less than 1% of all sites of primary presentations. We report the experience of the Department of Radiation Oncology at Ankara University Faculty of Medicine with radiation therapy in treatment of patients with stage I primary orbital NHL. Methods From February 1978 through August 1993, 14 patients with stage I primary orbital NHL were treated with radiation therapy. According to the Working Formulation classification, 8 patients had low-grade and 6 had intermediate-grade lymphomas. The most commonly used radiation therapy technique was a single anterior field with a Cobalt-60 unit, delivering 40 Gy in 2 Gy daily fractions. Two patients with intermediate-grade lymphomas received the CHOP regimen following radiation therapy. Results Follow-up ranged from 0.8 to 18.3 years (median, 10.3 years). Local control was achieved in all patients. Two patients with low-grade lymphomas relapsed locally and were successfully salvaged with radiation therapy. Three patients with intermediate-grade lymphomas failed systemically. Salvage therapy consisted of combination chemotherapy for 2 of them but was unsuccessful. Overall survival probabilities at 2, 5 and 10 years were 78.6%, 61.1% and 52.4%, respectively, for the entire group of 14 patients. Overall, cause-specific and disease-free survival probabilities were higher for patients with low-grade lymphomas than for those with intermediate-grade lymphomas (P = 0.03, P = 0.03 and P = 0.06, respectively). Cataracts were observed in 9 and lacrimal disorders in 4 patients. Conclusions The study suggests that among stage I primary orbital NHL, low-grade lymphomas could be treated with radiation therapy alone, whereas combination chemotherapy could accompany radiation therapy for intermediate-grade lymphomas.

scholarly journals Prognostic factors in non-Hodgkin lymphomas

2000 ◽  
Vol 118 (1) ◽  
pp. 7-12 ◽  
Author(s):  
Karin Zattar Cecyn ◽  
José Salvador Rodrigues de Oliveira ◽  
Antônio Correia Alves ◽  
Maria Regina Regis Silva ◽  
José Kerbauy
Keyword(s):  
Prognostic Factors ◽  
Hodgkin Lymphoma ◽  
Low Grade ◽  
High Grade ◽  
Cns Involvement ◽  
Intermediate Grade ◽  
Non Hodgkin Lymphoma ◽  
Tumor Dissemination ◽  
Mediastinal Disease ◽  
Extranodal Disease

CONTEXT: In Hodgkin's disease, each clinical or pathologic stage can be related to the extent of the area involved and predicts the next anatomical region at risk for tumor dissemination. OBJECTIVE: To determine the best prognostic factors that could predict survival in non-Hodgkin lymphoma cases. DESIGN: A retrospective study. LOCATION: Department of Hematology and Transfusion Medicine, Universidade Federal de São Paulo - Escola Paulista de Medicina. PARTICIPANTS: 142 patients with non-Hodgkin lymphoma diagnosed between February 1988 and March 1993. MAIN MEASUREMENTS: Histological subset, Sex, Age, Race, B symptoms, Performance status, Stage, Extranodal disease, Bulk disease, Mediastinal disease, CNS involvement, BM infiltration, Level of DHL, Immunophenotype. RESULTS: In the first study (113 patients), the following variables had a worse influence on survival: yellow race (P<0.1); ECOG II, III e IV (P<0.1) and extranodal disease (P<0.1) for high grade lymphomas; constitutional symptoms (P<0.1), ECOG II, III e IV (P<0.1) and involvement of CNS (P<0.1) for intermediate grade and the subtype lymphoplasmocytoid (P=0.0186) for low grade lymphomas. In the second survey (93 patients), when treatment was included, the variables related to NHL survival were: CNS involvement (P<0.1) for high grade lymphomas, constitutional symptoms (P<0.1), ECOG II, III, IV (P=0.0185) and also CNS involvement (P<0.1) for the intermediate group. There were no variables related to the survival for low-grade lymphomas. CONCLUSIONS: The intermediate grade lymphomas were more compatible with data found in the literature, probably because of the larger number of patients. In this specific case, the treatment did not have an influence on the survival.

scholarly journals FREQUENCY OF BONE MARROW INVOLVEMENT IN CASES OF LYMPHOMA: A HOSPITAL BASED OBSERVATIONAL STUDY

2020 ◽  
pp. 1-3
Author(s):  
Surbhi Mahajan ◽  
Subhash Bhardwaj ◽  
Poonam Sharma
Keyword(s):  
Bone Marrow ◽  
Hodgkin Lymphoma ◽  
Hodgkin’S Lymphoma ◽  
Bone Marrow Involvement ◽  
Hodgkin's Lymphoma ◽  
Classical Type ◽  
Low Grade ◽  
High Grade ◽  
Intermediate Grade ◽  
Non Hodgkin Lymphoma

Background: In patients with lymphoma, bone marrow involvement is definite evidence of disseminated disease and hence assessment of bone marrow status in these patients provides important information for decisions regarding treatment. Aim: To determine frequency of bone marrow involvement in cases of lymphoma. Results: Out of 60 histologically confirmed lymphoma patients, 51(85%) patients were of Non Hodgkin’s lymphoma and 9 (15%) patients were of Hodgkin’s lymphoma. International working formulation was followed to classify Non Hodgkin Lymphoma into low, intermediate and high grade. The low grade Non Hodgkin lymphoma cases comprised of 41.18% (21/51), high grade 39.21% (20/51) and intermediate grade 19.61% (10/51) cases. Out of 9 Hodgkin lymphoma (HL) cases, 8 (88.9%) were of classical type and there was a single case (11.1%) of lymphocytic predominant Hodgkin’s lymphoma. 25 (41.7%) cases showed bone marrow infiltration by the atypical lymphomatous cells. Bone marrow involvement was seen in 47.05% (24/51) cases of NHL. Among Non Hodgkin lymphoma cases, maximum involvement was seen in low grade NHL 57.14% (12/21) followed by intermediate grade NHL 50% (5/10) & minimum was seen in high grade NHL 35% (7/20). Conclusion: Thorough examination of bone marrow in lymphoma patients can increase the diagnostic accuracy as it may be the single most important finding in a patient with an otherwise localized disease thereby contributing to the prognosis and appropriate treatment modalities.

Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma

2008 ◽  
Vol 109 (3-5) ◽  
pp. 230-232 ◽  
Author(s):  
Anna Koumarianou ◽  
Pantelis Kountourakis ◽  
Theophanis Economopoulos
Keyword(s):  
Hodgkin Lymphoma ◽  
Low Grade ◽  
Non Hodgkin Lymphoma

Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events

Blood ◽  
2010 ◽  
Vol 115 (26) ◽  
pp. 5322-5328 ◽  
Author(s):  
Vanesa Caruso ◽  
Augusto Di Castelnuovo ◽  
Susana Meschengieser ◽  
Maria A. Lazzari ◽  
Giovanni de Gaetano ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Meta Analysis ◽  
Hematologic Malignancies ◽  
Incidence Rates ◽  
Clinical Implications ◽  
Low Grade ◽  
Thrombotic Risk ◽  
Non Hodgkin Lymphoma ◽  
Thrombotic Complications ◽  
Exact Maximum Likelihood

AbstractThrombotic complications in hematologic malignancies have important clinical implications. In this meta-analysis we sought to obtain accurate estimates of the thrombotic risk in lymphoma patients. Articles were searched in electronic databases and references. Eighteen articles were identified (29 cohorts, 18 018 patients and 1149 events). Pooled incidence rates (IRs) were calculated by the use of a method based on the exact maximum likelihood binomial distribution. The global IR of thrombosis was 6.4% (95% confidence interval [CI] 6.0%-6.8%). The global IRs of venous or arterial events were 5.3% (95% CI, 5.0%-5.7%) and 1.1% (95% CI, 0.9%-1.2%), respectively. The IR of thrombosis observed in subjects with non-Hodgkin lymphoma (NHL) was 6.5% (95% CI, 6.1%-6.9%), significantly greater than that observed for patients with Hodgkin lymphoma (4.7%; 95% CI, 3.9%-5.6%). Within NHL, patients with high-grade disease had a greater risk of events (IR 8.3%; 95% CI, 7.0%-9.9%) than low-grade disease (IR 6.3%; 95% CI, 4.5%-8.9%). This meta-analysis shows that the IR of thrombosis in lymphoma patients is quite high, especially in those with NHL at an advanced stage of the disease. These results may help better defining lymphoma populations at high thrombotic risk, to whom prophylactic approaches could be preferentially applied.

Sign in / Sign up

Export Citation Format

Share Document